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A B S T R A C T    
Introduction: There is a little evidence that routine follow-up of patients treated for early breast cancer (BC) to 
detect ibsilateral breast tumour recurrence (IBTR), or contralateral breast cancer (CBC), is either effective or 
offers any mortality benefits. We report our experience of following patients with early BC for recurrences and 
new primaries in order to determine the role of mammogram surveillance. 
Methods: Single centre, retrospective primary observational study was designed. Patients who had BC during year 
2001–2006 were included and followed for a minimum of ten years. Patients were divided based on the mo-
dalities of detecting BC in to screen detected group and clinically detected one i.e. symptomatic BC. These two 
groups were compared. 
Results: Total number of patients considered for analysis was 2530 (screen detected BC - 703 patients and 
symptomatic BC - 1827 patients). The rate of recurrence including regional and distant metastasis in screen 
detected BC group was 8% (57/703) and 2% (43/1827) in symptomatic one. However, the prevalence of IBTR/ 
CBC in the whole cohort was 2% (62/2530). Mammography surveillance identified 60% (37/62) of patients who 
had IBTRs/CBCs. 
Mammography surveillance detected 85% (29/34) of all IBTRs/CBCs in the screen detected BC group. In 
contrast, it picked up only 29% (8/28) in the other group (Chi squared 20.5 p < 0.005). 
Conclusions: Mammography surveillance is efficient for the screen detected BC group but not for the symptomatic 
one. Hence, it is worth suggesting different follow-up strategies for both groups. Further studies are therefore 
recommended.   
1. Introduction 
Breast cancer is the most common cancer in women [1]. The 5-year 
survival rate for invasive breast cancer is 85% [2]. Approximately 20% 
of patients will develop a systemic recurrence and die within 5 years. 
Moreover, in patients who undergo breast-conserving therapy (BCT), 
ipsilateral breast tumour recurrence (IBTR) occurs in 1–2% of patients 
each year and contralateral breast cancer (CBC) occurs at a rate of up to 
0.8% each year [3–5]. 
There is a little evidence that routine follow-up of patients treated for 
early breast cancer, in order to detect recurrence or a new primary 
disease, is either effective or offers any mortality benefit. Furthermore, 
there is lack of high-level evidence to support decisions about the 
frequency, timing, and duration of mammography surveillance. 
Literature review from 1990 onwards, the year of introduction of the 
national breast screening program in United Kingdom (UK) [6], showed 
that follow-up programs based on a regular physical exam and yearly 
mammogram appear to be as effective as the more intensive approaches 
[7–9]. The contribution of routine clinical examination (CE) for the 
detection of potentially treatable relapse was challenged several times. 
Montgomery and colleagues found recommendations for CE follow-up 
was based on weak evidence [10,11]. Additionally, there is also a 
paucity of evidence on the relative effectiveness of mammography in 
combination with other imaging such as MRI in follow up surveillance. 
These studies showed that additional imaging could result in unnec-
essary surgical procedures [12]. Some Studies reported that MRI and 
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mammography, combined with CE are most sensitive for detection of 
recurrences. However, none of these studies reported survival benefits 
over mammography only based surveillance [13]. 
Currently, most of the breast units in the UK follow patients with an 
annual mammography for five years or until the age of 50, after which 
patients enter the national screening program [14]. In 2013, the 
American Society of Clinical Oncology (ASCO) updated their clinical 
practice guidelines for follow-up. They recommended post-treatment 
mammogram to be obtained 1 year after the initial mammogram and 
at least 6 months after completion of radiation therapy; thereafter a 
yearly mammographic evaluation should be performed [15]. 
There are no data from randomised controlled trials demonstrating 
any benefit from mammography surveillance and therefore guidelines 
are based on expert opinion [16,17]. It was shown by non-randomised 
retrospective study that mammographic follow-up allowed early 
detection of relapse in the asymptomatic phase, which improved prog-
nosis relatively to symptomatic relapses [18]. Moreover, it was reported 
by the SEER database that early detection of CBC was associated with a 
mortality reduction compared with cases of CBC diagnosed at more 
advanced stages which supports the survival benefit of follow up with 
mammography [19]. 
It is now accepted that IBTR has an adverse influence on patient 
survival [20]. If patients experience IBTR, 40–50% will have further 
recurrence or develop distant disease subsequently. Therefore, the early 
detection of recurrence may be beneficial in terms of survival [21]. 
The objective of this study is to assess the rate of detection of IBTRs/ 
CBCs by mammography, and to compare this rate between patients 
whose original tumour was detected by screening and those who pre-
sented symptomatically. 
2. Methods 
2.1. Registration and ethics 
Research registry was undertaken through ISRCTN (Registration 
Unique Identifying number; ISRCTN37620362) [22]. 
The work has been reported in line with the STROCSS criteria [23]. 
Formal ethics committee clearance was not needed, as this was a 
service evaluation project. 
2.2. Cohort study design 
This is a single centre, retrospective primary observational study. All 
patients diagnosed with primary BC from 2001 to 2006 were identified 
using the cancer database at the Breast unit in Cambridge University 
Hospitals, NHS Foundation Trust, UK. 
All patients were followed up for at least 10 years or until the 
development of a second cancer (i.e. IBTR or CBC). Demographics and 
details of both primary and second cancers were documented. 
2.3. Cohort groups 
Patients were divided in to two groups according to mode of pre-
sentation of their BC (screen detected vs clinically detected) and mode of 
the diagnosis of their recurrences/new primaries (by mammogram or 
clinically). 
2.4. Participants and outcomes 
Details of patient’s who had recurrences/new primaries such as age, 
histopathology of cancer, time of recurrence and mode of detection were 
collected and analysed. 
IBTR is defined as any tumour in the same breast that was treated by 
conservative breast surgery for BC. On the other hand CBC is defined as 
any tumour in the other breast, after treatment of BC (Both breast 
conservative surgery and mastectomy were included). 
The following patients were excluded: patients with distant metas-
tasis or regional recurrence (chest wall, mastectomy scar or axilla), 
patients who were lost to follow-up or had no records, patients who died 
because of reasons other than breast cancer during ten years of follow-up 
and who were recurrence-free at the time of death. 
2.5. Statistical methods 
χ2 test was used to determine differences between subject groups. P 
value was considered significant if < 0.05. No power calculation done 
for this study, as the data were retrospective and observational. 
3. Results 
From January 2001 to June 2006 a total of 2552 patients had BC. 
Twenty-two patients had no records or were lost during follow-up and 
were hence excluded from the analysis. The cohort was divided into two 
groups according to the primary method of diagnosis, 703 patients had 
screen-detected breast cancer and 1827 patients presented symptomat-
ically. 2% (62/2530) had IBTRs/CBCs in both groups. Moreover 
mammography surveillance identified 60% (37/62) of them. 
The median age of recurrence was 69 (range 50–75) in the screen- 
detected BC group and 68 (45–90) in the symptomatic one. 
The IBTRs/CBCs in the screen and clinically detected BC groups 
were 8% (57/703) and 2% (43/1827) respectively. Table 1 shows 
summary of IBTRs/CBCs in both groups. 
Screen-detected BC represented 55% (34/62) of all patients who had 
another cancer. The remaining 45% (28/62) of patients belonged to the 
symptomatic group. 
Furthermore, mammography surveillance detected 85% (29/34) of 
all IBTRs/CBCs that developed in screen-detected BC group. On the 
other hand only 28% (8/28) of them in clinically detected group were 
picked up by mammogram. In fact the majority of this group i.e. 72% 
(20/28), presented clinically as they did first time (Table 2) (p < 0.005). 
Pathology of 25 patients who developed IBTRs/CBCs that were 
missed by mammogram and detected clinically is illustrated in Table 3. 
For those who were diagnosed by mammogram, 72% (21/29) of 
them had their IBTRs/CBCs picked up in the first five years of follow-up 
for screen-detected BC patients. However, the opposite was the case for 
symptomatic group. As only 37% (3/8) of them were detected in the first 
five years of follow-up by mammogram (Fig. 1). 
4. Discussion 
Our study showed that mammography surveillance of patients who 
were treated for primary BCs is of a value. It detected 60% of patients 
who had IBTRs or CBCs. 
Interestingly, when we divided patients in to two main groups, 
symptomatic and screen detected BCs, mammography surveillance 
was of more value in detecting IBTRs/CBCs in the screen-detected BC 
group than in the symptomatic one. Mammography surveillance picked 
up 85% of IBTRs/CBCs in the screen-detected BCs group that represent 
55% of all patients who had IBRTs/CBCs in the cohort. On the other 
hand, mammogram showed only 28% in the symptomatic group. This 
difference was statistically significant (p < 0.005). 
Table 1 
Summery of IBTRs/CBCs in screen and clinically-detected BC group.   
Screen detected BC group 
(n = 57) 
Clinically detected BC group 
(n = 43) 
IBTR 21/57 (37%) 25/43 (58%) 
CBC 13/57 (23%) 3/43 (7%) 
Regional 
recurrence 
3/57 (3%) 11/43 (26%) 
Systematic 
recurrence 
20/57 (35%) 4/43 (9%)  
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Despite of the small number of recurrences/new primaries (n = 62), 
our study has shown that it is justified to consider the mode of detecting 
primary BCs as one of characteristics to personalise follow-up strategies. 
The stratification of patients based on how likely they are to get IBTRs/ 
CBCs, in order to ensure the maximum benefit and the optimal use of 
resources was already recommended by Robertson and colleagues [13]. 
However none has clearly mentioned before in the literature that 
mammographic detection rate might be affected by the mode of primary 
BCs presentation. Furthermore, there was no mention of using the mode 
of detecting BCs as a possible guide to stratify the follow-up strategy. 
Our results demonstrated that 72% of the IBTRs/CBCs that were 
detected by mammography in the screen-detected group were found in 
the first five years of follow up. On the other hand, in the symptomatic 
group, 77% of them presented after five years of mammography sur-
veillance. There was no explanation for such contrasting results. The 
small number of this cohort may have implications on how much these 
results could reflect an actual trend. Hence it is difficult to make any 
comments or recommendations regarding the duration of follow-up or 
its frequency. Furthermore it is statistically insignificant (p = 0.067). 
From our literature review we could not find a study that compares 
the effect of different intervals on detecting recurrence and its stage. 
Furthermore there is paucity of strong evidences on the ideal duration of 
follow up. Most guidelines recommend either 12 monthly or 6–12 
monthly surveillance following completion of adjuvant therapies. These 
recommendations were based on expert opinion due to the paucity of 
supporting data. Arasu et al. recommended continuing doing semi- 
annual surveillance [24] when other studies concluded that interval of 
6 months is of low value [25,26]. Optimal duration and interval for 
mammogram follow-up stays uncertain [27]. Customising follow up 
duration and frequency to patients was suggested. Higher risk patients 
may benefit from annual mammography while triennial mammography 
may suffice as a cost-effective strategy for lower risk patients [13,15,27, 
28]. Ciatto and colleagues supported long term follow up of patients for 
10 years [29]. The on going Mammo 50 trial that aims to investigate the 
optimum frequency and duration of follow up mammograms in patients 
older than 50 should provide evidence that will contribute to the debate. 
It is likely to produce useful data as it is multi-centric, randomised, 
controlled, phase III trial [30]. 
In our study, patients who had cancers that were missed by 
mammogram were analysed in depth, the characteristics (type, grade, 
LVI and receptor status) of both primary BC and/CBCs were studied, in 
order to find out whether these characteristics played a role in being 
missed by mammograms. For instance it is well known that mammog-
raphy has limitation in detecting invasive lobular cancer and often un-
derestimates the disease [31]. However, our findings showed no specific 
tumour characteristics that explained why IBTRs/CBCs were missed by 
mammograms. 
Breast tissue high density is another factor to be blamed for missing 
tumours in mammograms. In our study, there was a limitation for 
accessing the radiology films to assess the density of the breast tissue of 
patients who had IBTRs/CBCs missed by mammogram, as films were not 
available in majority of the patients who were missed by mammogram. 
Therefore, age was considered as a guide of breast density, based on the 
fact that young patients have more dense breasts, which may reduce the 
efficacy of a mammogram [32]. We found no observed difference in the 
age groups of patients who had IBTRs/CBCs, regardless of whether they 
were detected by mammogram or clinically at the time of presentation. 
Hence, breast density was not considered as a factor that contributed to 
missing recurrence or CBC in this study. 
We acknowledged few limits of our study that can be underlined. 
One of them is being from a single centre. This may lead to under esti-
mation of real status. Another one is loss of follows ups, absence of re-
cords and loss of data all contributed to loss of participants; 3% of BCs 
were excluded due to absent records. 
Having recognised the limitation of this study, it is still worth rec-
ommending, that follow-up surveillance for screen-detected BC patients 
should be with a mammogram, more frequently, for a longer duration, 
and with less clinical visits. On the other hand, patients who present 
with palpable primary BC should be followed clinically with less 
frequent mammograms and a shorter duration. Further study is there-
fore recommended. 
5. Conclusion 
Mammogram follow-up is efficient for the screen-detected group but 
not for the clinically detected once. Hence, it is worth suggesting 
different follow-up strategies for both groups after further study on 
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Table 2 
Detection modes of IBTRs/CBCs.   
Screen detected BC 
group 
n = 34 (%) 
Clinically detected BC 
group 
n = 28 (%) 
IBTRs/CBCs detected by 
mammogram 
29/34 (85%) 8/28 (28%) 
IBRTs/CBCs detected clinically 5/34 (15%) 20/28 (72%)  
Table 3 
Pathology of IBTRs/CBCs detected clinically.  
IBTRs/CBCs Pathology 
PBCs Pathology DCIS LCIS IDC ILC Others Total 
DCIS – – 4 – 1 5 
LCIS – – – – – – 
IDC – – 17 – – 17 
ILC – – 1 2 – 3 
Others – – – – – – 
Total – – 22 2 1 25 
PBC- Primary Breast Cancer, DCIS –Ductal Carcinoma In Situ, LCIS –Lobular 
Carcinoma In Situ, IDC-Invasive ductal carcinoma, ILC-Invasive Lobular 
Carcinoma. 
Fig. 1. Mammogram detected recurrences in relation to time of presentation 
PBC- Primary Breast Cancer. 
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